Condition: Primary Immune Thrombocytopenia · Warm Autoimmune Hemolytic Anemia · Sponsor: Novartis Pharmaceuticals
This study is intended to explore the efficacy and safety of a second course of ianalumab after experiencing treatment failure in the pivotal Primary Immune Thrombocytopenia (ITP) trials (CVAY736I12301, CVAY736Q12301) and after loss of durable response in the pivotal Warm Autoimmune Hemolytic Anemia (wAIHA) trial (CVAY736O12301).
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111
Always discuss trial participation with your own doctor first.
| Novartis Investigative Site | Buenos Aires, Argentina | Withdrawn |
| Novartis Investigative Site | Roeselare, West-Vlaanderen, Belgium | Recruiting |
| Novartis Investigative Site | Guangzhou, Guangdong, China | Recruiting |
| Novartis Investigative Site | Dalian, Liaoning, China | Recruiting |
| Novartis Investigative Site | Tianjin, China | Recruiting |
| Novartis Investigative Site | Ostrava, Poruba, Czechia | Recruiting |
| Novartis Investigative Site | Caen, France | Recruiting |
| Novartis Investigative Site | Rennes, France | Recruiting |
| Novartis Investigative Site | Jena, Thuringia, Germany | Recruiting |
| Novartis Investigative Site | Debrecen, Hajdu Bihar Megye, Hungary | Recruiting |
| Novartis Investigative Site | Florence, FI, Italy | Recruiting |
| Novartis Investigative Site | Roma, RM, Italy | Recruiting |
+ 13 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07039422